Rovaldi Christopher
Known title: Chief Operating OfficerCIK: 0001706040
Associated companies
Transaction History
| KROS | ▲ Buy | Grant | 60,000 | $0 | 2/18/2025 | View on chart |
| KROS | ▲ Buy | Option Exercise | 1,728 | $28K | 4/6/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,728 | $112K | 4/6/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 864 | $14K | 4/1/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 2 | $109 | 4/1/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 104 | $6K | 4/1/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 287 | $16K | 4/1/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 366 | $21K | 4/1/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 105 | $6K | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.